276 related articles for article (PubMed ID: 28463030)
1. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects.
Ruan X; Kubba A; Aguilar A; Mueck AO
Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):183-190. PubMed ID: 28463030
[TBL] [Abstract][Full Text] [Related]
2. The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review.
Bitzer J; Römer T; Lopes da Silva Filho A
Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):172-182. PubMed ID: 28447864
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
Falsetti L; Galbignani E
Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
[TBL] [Abstract][Full Text] [Related]
4. Prescribing of cyproterone acetate/ethinylestradiol in UK general practice: a retrospective descriptive study using The Health Improvement Network.
Cea Soriano L; Asiimwe A; García Rodriguez LA
Contraception; 2017 Mar; 95(3):299-305. PubMed ID: 27769766
[TBL] [Abstract][Full Text] [Related]
5. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy.
Franks S; Layton A; Glasier A
Hum Reprod; 2008 Feb; 23(2):231-2. PubMed ID: 18083746
[TBL] [Abstract][Full Text] [Related]
6. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): observational studies using the UK General Practice Research Database.
Seaman HE; de Vries CS; Farmer RD
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):427-36. PubMed ID: 15269926
[TBL] [Abstract][Full Text] [Related]
8. The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate.
Eden JA
Med J Aust; 1991 Nov; 155(10):677-80. PubMed ID: 1834923
[TBL] [Abstract][Full Text] [Related]
9. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism.
Karrer-Voegeli S; Rey F; Reymond MJ; Meuwly JY; Gaillard RC; Gomez F
Medicine (Baltimore); 2009 Jan; 88(1):32-45. PubMed ID: 19352298
[TBL] [Abstract][Full Text] [Related]
10. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.
Seaman HE; de Vries CS; Farmer RD
Hum Reprod; 2003 Mar; 18(3):522-6. PubMed ID: 12615818
[TBL] [Abstract][Full Text] [Related]
11. Effect of cyproterone acetate/ethinyl estradiol combination on periodontal status and high-sensitivity C-reactive protein levels in women with polycystic ovary syndrome: a cross-sectional study.
Singhal R; Tewari S; Sharma R; Singhal S; Tanwar N; Sangwan A
Quintessence Int; 2024 Apr; 55(4):274-285. PubMed ID: 38391191
[TBL] [Abstract][Full Text] [Related]
12. Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms.
Acién P; Mauri M; Gutierrez M
Hum Reprod; 1997 Mar; 12(3):423-9. PubMed ID: 9130733
[TBL] [Abstract][Full Text] [Related]
13. Differences in the use of combined oral contraceptives amongst women with and without acne.
Seaman HE; de Vries CS; Farmer RD
Hum Reprod; 2003 Mar; 18(3):515-21. PubMed ID: 12615817
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone as a single agent for long-term therapy of hirsute patients.
Spritzer PM; Lisboa KO; Mattiello S; Lhullier F
Clin Endocrinol (Oxf); 2000 May; 52(5):587-94. PubMed ID: 10792338
[TBL] [Abstract][Full Text] [Related]
15. [The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type].
Gollnick H; Albring M; Brill K
Ann Endocrinol (Paris); 1999 Sep; 60(3):157-66. PubMed ID: 10520404
[TBL] [Abstract][Full Text] [Related]
16. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
17. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
Falsetti L; Pasinetti E
Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome.
Falsetti L; Gambera A; Tisi G
Hum Reprod; 2001 Jan; 16(1):36-42. PubMed ID: 11139533
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study.
Karakurt F; Sahin I; Güler S; Demirbas B; Culha C; Serter R; Aral Y; Bavbek N
Adv Ther; 2008 Apr; 25(4):321-8. PubMed ID: 18389188
[TBL] [Abstract][Full Text] [Related]
20. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
